WaPo Admits Internal DC Police Scandal Over Manipulated Crime Stats

 Five weeks ago, White House Deputy Chief of Staff Stephen Miller announced that there was an ongoing DOJ investigation into whether Washington D.C. officials manipulated crime statistics - calling it a "massive scandal." 

Specifically, Miller said:

"There's even accusations that murders and homicides were reported as accidents."

See 55 second mark:

BREAKING: Stephen Miller just said that the DOJ is working on exposing how Democrat controlled cities have been MANIPULATING crime data!

"When we ultimately share the results, it will STUN you!"

"There are even accusations that m*rders and homIcides were reported as accidents… pic.twitter.com/izRxYynIRz

— Gunther Eagleman™ (@GuntherEagleman) August 25, 2025

One day after Miller's late-August announcement, National Police Association spox Betsy Smith told ABC4 News in a little-noticed report that "Commanders and supervisors were having the initial responding officers write the report differently than what they were called to, or different than what they physically saw on the scene."

And while the DC Police Department has been run by Democrats for decades - frustrated cops have been talking to the DOJ and have receipts, presented with a bow by D.C. Police Union Chairman Greggory Pemberton. Read on... 

Greggory Pemberton, chairman of the D.C. Police Union (Photo: Michael A. McCoy via The Washington Post)

On Sunday, the Washington Post revealed internal accusations that "managers were recording serious crimes as more minor ones to make their police districts appear safer or avoid the ire of top department brass" - and that officers and supervisors 'clashed' over "whether an offense was a robbery or a theft, or whether a weapon used in an assault qualified as potentially deadly."

The frustrated officers "kept lists, documenting cases where they believed a higher-up improperly classified a crime as a lesser offense," with one noting 150 such instances in March of 2024 alone in which staff in the Southeast D.C. police district believed offenses were in appropriately classified. 

"The police department is playing fast and loose with how they report their data so that they can report favorably to the citizens about crime, and I don’t think it’s fair to the city," said Pemberton - who's been assisting the Trump administration and Congressional Republicans with 'information compiled by officers.'

So, a group of pissed off cops within the DC police department have been fighting with superiors and keeping notes over misclassified crimes, and kept notes. Now they're working with the feds to blow the lid. Or as WaPo puts it - "found a receptive audience."

We're sure the galaxy brains over at FactCheck.org are getting right on that correction after saying President Trump 'wrongly' claimed that his DC crackdown resulted in 11 days with no murders, the "first time that’s taken place in years." They of course make no mention of the DOJ / Congressional investigation Miller announced two days earlier. 

And of course, a July report by NBC Washington that MPD District 3 Commander Michael Pulliam was suspended and placed under investigation for allegedly manipulating crime data - however Stephen Miller said it was being done "on a widespread basis" - so more than just that sacrificial lamb.

WaPo Spin

Of course this Sunday night report is all about frontrunning the DOJ release - and narrative control. Such as that it could have simply been an initial lack of evidence - writing that "Criminologists say [zh: wait for it] classifying crimes is an often subjective and evolving process: Incidents can be redefined as investigators uncover more evidence, and disagreements don’t necessarily point to corruption." And who's the one criminologist they cited? "Alexis Piquero, a criminologist at the University of Miami who led the Bureau of Justice Statistics during the Biden administration," who "cautioned against jumping to conclusions that D.C. police were purposefully concealing violent crimes."

Right, yes. 

Recall that during the 2024 election, Democrats insisted that crime had fallen under the Biden administration, contrary to your lying eyes. They smugly pointed to FBI crime stats published in 2023 by Biden's FBI - showing that the nation's violent crime rate had fallen in 2022 by 1.7%. Leftist pundits and academics alike used it for a collective 'ackchyually' whenever Trump and his allies would point out the rampant crime gripping Democrat-run cities.

Psst you still have time to delete this one, like you do most of your others. https://t.co/DoUx7FT3mp

— zerohedge (@zerohedge) October 5, 2025

Then, in the home stretch of the election when Trump was clearly ahead (and before Kash Patel could go 'Ah-ha!'), the 2022 figures were revised - revealing that crime had actually increased by 4.5% in 2022. This textbook Ministry of Truth 'correction' was uncovered by John Lott Jr. and published Oct. 16. 

Amazing...

False reporting has been happening at a very large scale

— Elon Musk (@elonmusk) October 5, 2025 

https://www.zerohedge.com/political/wapo-admits-dc-cops-have-been-manipulating-crime-stats-after-white-house-bombshell

"Freedom" Shirts Reportedly Banned In Kansas Elementary Public School

 by Jonathan Turley,

An elementary school in Kansas has raised a novel question under the First Amendment: whether the freedom of speech includes the right to use the word “freedom.” According to some media reports, Arbor Creek Elementary Principal Melissa Snell stopped the wearing of shirts reading “Freedom,” which have become popular after the assassination of Charlie Kirk. The move is clearly a violation under the First Amendment, in my view.

Libs of TikTok posted an email exchange between Arbor Creek Elementary Principal Melissa Snell and an (unnamed) individual in which Snell confirmed the ban. The email stated: “I just want to make sure that you have told your staff to not wear those ‘Freedom’ shirts to school anymore. Thank you.”

Snell allegedly responded: “Yes, I have. Was there someone in particular that you are referring to? If you don’t mind me asking.”

Our crackerjack investigatory unit at Res Ipsa was able to find that person for Snell from what appears to be video of students of Arbor Creek:

Notably, the Olathe Public Schools district itself sells “We All Belong Together” shirts via its Department of Culture and Belonging. However, “Freedom” shirts were banned, at least temporarily.

Deputy Superintendent Lachelle Sigg wrote to the school community that the district “remain[s] committed to […] honoring all first amendment rights and ensuring that personal expression does not disrupt the educational setting.”

If so, that commitment is more rhetorical than actual.

Superintendent Brent Yeager confirmed the emails that Libs of TikTok had posted earlier in the week, but suggested that it was temporary as Snell “reviewed district practices.”

I fail to see why Snell had to suspend the wearing of such shirts pending review. This is clearly a content-based limitation on speech.

In Tinker v. Des Moines Independent Community School District (1969), the Supreme Court upheld the right of students to wear armbands protesting the Vietnam War, famously writing, “It can hardly be argued that either students or teachers shed their constitutional rights to freedom of speech or expression at the schoolhouse gate.”

This does not involve the type of “lewd,” “vulgar,” “indecent,” or “plainly offensive” speech discussed in cases such as Bethel School District v. Fraser (1986). It is a statement of solidarity between the freedom of speech, a statement made more poignant and urgent with the murder of Kirk for exercising that right.

It is also not a celebration of unlawful conduct, as in Morse v. Frederick (2007), as opposed to the exercise of our most “Indispensable Right.”

It is a good thing that Joseph Cinqué did not try to enroll at Arbor Creek Elementary:

*  *  *

Jonathan Turley is the Shapiro Professor of Public Interest Law at George Washington University. He is the author of the bestselling book “The Indispensable Right: Free Speech in an Age of Rage.”

https://www.zerohedge.com/political/freedom-shirts-reportedly-banned-kansas-elementary-public-school

OneMedNet selects Palantir to power healthcare data analytics platform

 OneMedNet Corporation (NASDAQ:ONMD) has entered into a multi-year agreement with Palantir Technologies (NASDAQ:PLTR) to enhance its healthcare data analytics capabilities, according to a press release statement.

The collaboration will integrate Palantir’s Artificial Intelligence Platform with OneMedNet’s provider network, which currently provides access to more than 5 billion administrative claims and 131 million clinical exams across 1,750+ provider sites. 

Under the agreement, OneMedNet will utilize Palantir’s technology to deliver anonymized, regulatory-grade clinical data to life sciences, medical device, and research organizations. The platform aims to accelerate the development of medical solutions by providing faster data discovery and more accurate data delivery.

https://www.investing.com/news/company-news/onemednet-selects-palantir-to-power-healthcare-data-analytics-platform-93CH-4272283

Spruce Biosciences stock soars after receiving FDA Breakthrough Therapy status

 Spruce Biosciences (NASDAQ:SPRB) stock surged 60% after the company announced it received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B.

The FDA designation, which expedites development and regulatory review for promising therapies addressing serious conditions, was supported by integrated long-term clinical data showing normalization in cerebral spinal fluid heparan sulfate non-reducing end (CSF HS-NRE). Notably, the FDA confirmed that CSF HS-NRE could serve as a surrogate biomarker reasonably likely to predict clinical benefit, potentially enabling accelerated approval.

Spruce Biosciences, a late-stage biopharmaceutical company focused on developing therapies for neurological disorders, remains on track to submit its Biologics License Application for TA-ERT in the first quarter of 2026.

https://www.investing.com/news/stock-market-news/spruce-biosciences-stock-soars-after-receiving-fda-breakthrough-therapy-status-93CH-4272612

'Young Wall Streeters say this is the irreplaceable human skill in the AI era'

 Goldman Sachs’ summer interns say emotional intelligence is the one skill artificial intelligence can’t replace. 

In a survey of roughly 2,150 interns, 66% ranked emotional intelligence as the most irreplaceable workplace skill, underscoring the growing value of empathy and communication in an increasingly automated world.

Leadership and influence followed at 48%, highlighting that interpersonal judgment and team guidance remain key differentiators even as technical tasks become more automated.

A handful of singularity fans (2%) believed AI would eventually replicate all human skills.

For its part, OpenAI's ChatGPT said the interns "nailed it."

"As AI keeps getting sharper at logic, language, and pattern recognition, what’s left — what truly matters — are the things that aren’t just data: empathy, timing, tone, curiosity, humor. The small human calibrations that make people trust, follow, and feel seen. Those don’t scale neatly into code," ChatGPT said when prompted about the results of the survey.

"It’s also a nice twist of humility coming from Goldman interns — people already tuned for high-stakes precision admitting that emotional fluency may be the ultimate differentiator."

 

Goldman Sachs
https://www.msn.com/en-us/money/markets/young-wall-streeters-say-this-is-the-irreplaceable-human-skill-in-the-ai-era/ar-AA1NWpOv

Niagen Bioscience raises 2025 sales outlook on NAD+ market growth

 Niagen Bioscience, Inc. (NASDAQ:NAGE) announced Monday it has increased its full-year 2025 net sales growth forecast to between 25% and 30% year-over-year, up from its previous projection of 22% to 27%. The company has demonstrated strong execution, with revenue growing 35.9% over the last twelve months and maintaining healthy gross margins of 63.6%.

The company, which specializes in NAD+ (nicotinamide adenine dinucleotide) science and healthy aging research, cited recent regulatory developments as potentially beneficial to its business outlook. According to the company, the FDA’s reversal of previous rulings on the DSHEA drug preclusion rule relating to NMN (nicotinamide mononucleotide) could increase awareness of the NAD+ precursor market. 

Niagen Bioscience’s core product is Niagen, a patented nicotinamide riboside (NR) supplement designed to boost NAD+ levels. The company manufactures its products in the United States.

"Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of science is valuable for public health and for Niagen Bioscience," said Rob Fried, CEO of Niagen Bioscience, in the press release.

The company also noted that its market surveillance program has tested various NAD+ supplements on the market and claims that NMN supplements currently available infringe upon existing patent portfolios related to NMN crystallization.

https://www.investing.com/news/company-news/niagen-bioscience-raises-2025-sales-outlook-on-nad-market-growth-93CH-4272770

Skye's shares crater as CB1 blocker fails to reduce weight in phase 2 obesity study

 Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class.

The biotech had been evaluating a 200-mg weekly subcutaneous dose of the drug, called nimacimab, as a monotherapy and in combination with semaglutide—the ingredient in Novo Nordisk’s blockbuster Wegovy—compared to semaglutide alone in the midstage trial of 136 patients who are overweight or with obesity.

Nimacimab alone demonstrated weight loss of just 1.52%, barely above the placebo group’s 0.26% weight reduction and a fraction of the 10.25% weight loss seen among the semaglutide cohort. Shares in the company tumbled Monday morning, down more than 60% in early premarket trading. 

Skye Chief Medical Officer Puneet Arora, M.D., suggested “lower-than-expected drug exposure” from the 200-mg dose “may have limited the observed effect.”

Instead, the biotech was keen to point to the 13.2% average weight loss among patients taking the nimacimab-semaglutide combo.

“The combination of nimacimab with semaglutide produced a clinically meaningful additional weight loss that exceeded semaglutide alone, with a favorable tolerability profile even in patients who achieved the highest exposure levels,” Arora said in the Oct. 6 release.

“With our preclinical data, toxicology safety margins, and PK modeling, we believe we have a path to support higher dosing, and we are evaluating the next stage of development to optimize dosing in potential future clinical trials," the CMO added.

It marks the latest setback for hopes of getting a CB1 blocker to market as a weight loss treatment. Sanofi had a CB1 obesity drug approved in Europe, but authorities withdrew the approval in 2009 after studies found it doubled the risk of psychiatric disorders. More recently, Roche took a chance on the modality when the Swiss pharma penned a $1.1 billion deal for Inversago Pharma in 2023.

The lead drug from that study was also tied to neuropsychiatric side effects. Roche went on to drop a second CB1 drug from Inversago, although there were no signs of similar side effects influencing that decision.

In this morning’s release, Skye stressed that “no neuropsychiatric concerns were observed” in its phase 2 study of nimacimab. In fact, the drug demonstrated a “clean” safety profile, according to the biotech, with none of the increased gastrointestinal adverse events seen with some weight loss drugs.

More than a quarter of patients across the trial discontinued their treatment, including 30% of the placebo cohort, 29% of the nimacimab monotherapy group and 26% of those who received the nimacimab-semaglutide combo. However, only 3.7% of discontinuations were due to adverse events, Skye said.

Undeterred by this morning’s top-line fail, Skye pointed to “multiple factors” it believes justify evaluating the drug at higher doses and alluded to a potential fresh phase 2a study down the line.

https://www.fiercebiotech.com/biotech/skyes-shares-crater-cb1-blocker-fails-reduce-weight-phase-2-obesity-study